Anavex Life Sciences (NASDAQ:AVXL) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Volatility & Risk
Anavex Life Sciences has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
This table compares Anavex Life Sciences and Bioanalytical Systems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Anavex Life Sciences||N/A||-117.06%||-94.17%|
Insider & Institutional Ownership
14.6% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 6.0% of Bioanalytical Systems shares are held by institutional investors. 12.3% of Anavex Life Sciences shares are held by company insiders. Comparatively, 7.8% of Bioanalytical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
This is a summary of current ratings and price targets for Anavex Life Sciences and Bioanalytical Systems, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Anavex Life Sciences||0||0||3||0||3.00|
Anavex Life Sciences currently has a consensus target price of $9.00, suggesting a potential upside of 160.87%. Given Anavex Life Sciences’ higher possible upside, equities analysts plainly believe Anavex Life Sciences is more favorable than Bioanalytical Systems.
Valuation & Earnings
This table compares Anavex Life Sciences and Bioanalytical Systems’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Anavex Life Sciences||N/A||N/A||-$17.45 million||($0.39)||-8.85|
|Bioanalytical Systems||$26.35 million||0.79||-$190,000.00||N/A||N/A|
Bioanalytical Systems has higher revenue and earnings than Anavex Life Sciences.
Anavex Life Sciences beats Bioanalytical Systems on 6 of the 11 factors compared between the two stocks.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis. It is also developing ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was founded in 2006 and is based in New York, New York.
Bioanalytical Systems Company Profile
Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.